Dr. Aaron Weitzman brings over two decades of expertise in oncology drug development to his role as Acting Chief Medical Officer. A U.S.-trained, board-certified medical oncologist, Ron has been shaping the biopharmaceutical industry since 1999, with extensive experience across all phases of clinical development, from Phase 1 through to late-stage and confirmatory clinical trials. His work spans both solid tumors and hematological malignancies, and he has collaborated closely with global regulatory authorities, including the FDA, EMA, Health Canada, and Japan's PMDA.

During his tenure at Exelixis, Ron led the development of cabozantinib (XL184) for prostate cancer, overseeing two pivotal Phase 3 registrational studies. Known for his leadership and mentorship, Ron has successfully managed teams of varying sizes and remains passionate about fostering the growth of colleagues in the field.

In 2014, Ron founded Weitzman Consulting Group LLC, to provide strategic guidance in oncology drug development, leveraging his vast expertise to drive innovation and improve patient outcomes.